On Jul. 5, 2022, Tgen and Northern Arizona University announced that a research team found that the vaccine generates antibodies that target regions of the SARS-CoV-2 spike protein that are unique to the new virus, while also targeting regions of the protein that are shared or conserved among many coronaviruses.